| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
17 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-11 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Addex Therapeutics Ltd is a biopharmaceutical company that specializes in developing novel drugs to treat diseases of the central nervous system (CNS). The company is headquartered in Geneva, Switzerland and is publicly traded on the SIX Swiss Exchange.
Addex is focused on developing drugs that target the gamma-aminobutyric acid (GABA) system, which plays a critical role in the regulation of nerve cell activity in the brain. By modulating GABA receptors, Addex aims to develop drugs to address various CNS disorders, including Parkinson's disease, migraine, epilepsy, and addiction.
The company has a proprietary technology platform called allosteric modulation, which allows for the discovery and development of drugs that selectively enhance or inhibit specific GABA receptors. This approach offers the potential for more targeted and safer drugs compared to traditional approaches.
Addex's pipeline includes several drug candidates, including dipraglurant for the treatment of Parkinson's disease and levodopa-induced dyskinesia, as well as ADX71149 for the treatment of migraine and epilepsy. These drugs are currently in different stages of clinical development, with some in Phase 2 clinical trials.
In addition to its own drug development programs, Addex also collaborates with pharmaceutical and biotechnology companies to advance its technologies and drug candidates. The company has established partnerships with companies such as Janssen Pharmaceuticals, Indivior, and the National Institute on Drug Abuse.
Overall, Addex Therapeutics Ltd is focused on advancing innovative drugs targeting the GABA system to address unmet medical needs in the field of CNS disorders.
Company Address: Chemin des Mines 9 Geneva 1202
Company Phone Number: 884 1555 Stock Exchange / Ticker: NASDAQ ADXN
|
0.000%
100 %